ArticleResearch square2025
Remote AI Screening for Parkinson's Disease: A Multimodal, Cross-Setting Validation Study.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
20 authors.
Funding
Abstract
PARK is a web-based artificial intelligence (AI) tool for remote screening of Parkinson's disease (PD) using video and audio recordings of speech, facial expression, and motor tasks performed via webcam. The study draws on data from 1,865 participants across diverse global demographics and recording environments, including supervised clinical settings and unsupervised home use. On three independent test sets (n=389; 188 with PD), PARK achieved strong predictive performance on classifying individuals with and without PD, with accuracy ranging from 80.2% to 80.6% and area under the receiver operating characteristic curve (AUROC) from 0.85 to 0.87. When evaluated on 30 randomly selected individuals, PARK's assessments were 83.7% accurate and showed high agreement with three movement disorder specialists. The model generalized well across age, sex, and ethnic subgroups and incorporated mechanisms to withhold uncertain predictions to support safe use in unsupervised settings. Usability studies confirmed high participant satisfaction and preference for remote screening. These findings support the potential of PARK as an accessible, scalable, and clinically aligned tool to identify individuals with PD when access to traditional healthcare settings is scarce.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.